Immune checkpoint inhibitors: a patent review (2010-2015)

Nivolumab in Nonsquamous Non–Small-Cell Lung Cancer

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Intellectual property issues of immune checkpoint inhibitors

(2015) Ulrich Storz   mAbs

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Cancer and the gut microbiota: An unexpected link

(2015) Laurence Zitvogel et al.   Science Translational Medicine

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

The co-receptor BTLA negatively regulates human V 9V 2 T-cell proliferation: a potential way of immune escape for lymphoma cells

(2013) J. Gertner-Dardenne et al.   BLOOD

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

(2013) Jérôme Galon et al.   JOURNAL OF PATHOLOGY

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

(2012) J. Faget et al.   CANCER RESEARCH

ENTPD1/CD39 is a promising therapeutic target in oncology

(2012) J Bastid et al.   ONCOGENE

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells

(2011) Christiane A. Opitz et al.   PLoS One

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation

(2009) J. Yu et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines

(2009) William D. Hastings et al.   EUROPEAN JOURNAL OF IMMUNOLOGY